EOSINOPHILIC GRANULOMATOSIS WITH POLYANGIITIS (CHURG-STRAUSS) (EGPA)

Clinical trials for EOSINOPHILIC GRANULOMATOSIS WITH POLYANGIITIS (CHURG-STRAUSS) (EGPA) explained in plain language.

Never miss a new study

Get alerted when new EOSINOPHILIC GRANULOMATOSIS WITH POLYANGIITIS (CHURG-STRAUSS) (EGPA) trials appear

Sign up with your email to follow new studies for EOSINOPHILIC GRANULOMATOSIS WITH POLYANGIITIS (CHURG-STRAUSS) (EGPA), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Completed 1

Real-World data shows mepolizumab may keep rare vasculitis in check Long-Term

Disease control Completed

This study followed 591 adults with eosinophilic granulomatosis with polyangiitis (EGPA) across Europe to see how well mepolizumab 300mg every 4 weeks works over the long term in everyday medical practice. Researchers looked at disease control, lung function, and safety by review…

Matched conditions: EOSINOPHILIC GRANULOMATOSIS WITH POLYANGIITIS (CHURG-STRAUSS) (EGPA)

Sponsor: European EGPA Study Group • Aim: Disease control

Last updated Jun 27, 2026 12:34 UTC

EOSINOPHILIC GRANULOMATOSIS WITH POLYANGIITIS (CHURG-STRAUSS) (EGPA)

Get alerted when new EOSINOPHILIC GRANULOMATOSIS WITH POLYANGIITIS (CHURG-STRAUSS) (EGPA) trials appear

Real-World data shows mepolizumab may keep rare vasculitis in check Long-Term